Finance

Lists
QTTB:NASDAQ
Q32 Bio Inc
$10.68
-0.37%
(-0.040) 1D
Sep 11, 11:25:11 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for QTTB...
Open
$10.82
High
$10.93
Low
$10.64
Mkt. cap
317.94M
Avg. vol.
462.20K
Volume
186.67K
P/E ratio
3.57
52-wk high
$23.57
52-wk low
$1.69
EPS
$2.99
Beta
0.21
Shares outstanding
29.77M
No. of employees
22
Open
$10.82
High
$10.93
Low
$10.64
Mkt. cap
317.94M
Avg. vol.
462.20K
Volume
186.67K
P/E ratio
3.57
52-wk high
$23.57
52-wk low
$1.69
EPS
$2.99
Beta
0.21
Shares outstanding
29.77M
No. of employees
22
News stories
From web sources and news partners
About Q32 Bio Inc
CEO-
Employees22
Founded2017
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websiteq32bio.com
Analyst ratings
Based on 5 analysts giving stock ratings to QTTB in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for QTTB in the last 3 months.
Highest
Current $10.68
$59.00 (+452.43%)
Average
$41.00 (+283.90%)
Lowest
$34.00 (+218.35%)
Analyst
Recommendation
Action
Price target
Projected
Date
Judah Frommer
Morgan Stanley
Buy
Initiated
$34.00
+218.4%
08/24/2026
Jay Olson
Oppenheimer
Buy
Maintained
$40.00
+274.5%
08/06/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$59.00
+452.4%
08/06/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$36.00
+237.1%
08/05/2026
Joseph Catanzaro
Mizuho Securities
Buy
Reiterated
$36.00
+237.1%
07/13/2026
Richard Poland
Wells Fargo
Hold
Maintained
$10.00
-6.4%
05/28/2026
Unknown Analyst
Wells Fargo
Hold
Maintained
$10.00
-6.4%
05/28/2026
Unknown Analyst
Cantor Fitzgerald
Buy
Initiated
-
-
05/18/2026
Imogen Mansfield
Cantor Fitzgerald
Buy
Initiated
-
-
05/18/2026
Imogen Mansfield
Cantor Fitzgerald
Buy
Initiated
-
-
05/18/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
53.74M
-
-
Cost of goods sold
3.56M
3.32M
3.22M
4.26M
Cost of revenue
3.56M
3.32M
3.22M
4.26M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.02M
4.54M
4.50M
4.86M
Operating expense
4.02M
4.54M
4.50M
4.86M
Total operating expenses
7.58M
7.86M
7.72M
9.12M
Operating income
-7.58M
45.88M
-7.72M
-9.12M
Other non operating income
-12.00K
-12.00K
-79.00K
73.00K
EBT including unusual items
-7.39M
57.73M
-7.61M
-8.95M
EBT excluding unusual items
-7.39M
46.07M
-7.61M
-8.80M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-7.39M
57.73M
-7.61M
-8.95M
Net profit margin
-
107.43%
-
-
Earnings per share
-
-
-
-
Interest and investment income
500.00K
400.00K
392.00K
446.00K
Interest expense
-300.00K
-200.00K
-200.00K
-200.00K
Net interest expenses
200.00K
200.00K
192.00K
246.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-7.49M
45.97M
-7.63M
-9.03M
Gain or loss from assets sale
-
-11.74M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps